Clinical Trials
93 trialsNational Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
ASTEROID
Vastra Gotaland Region
ATLANTIC
AstraZeneca
358
Brown University
TRADE-hypo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CAIRE
Institut Bergonié
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
......SMARTEST Trial......
University Health Network, Toronto
ARION
UNICANCER
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
University of Kentucky
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Washington University School of Medicine
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute
SAVIMMUNE
Intergroupe Francophone de Cancerologie Thoracique
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial in Patients With Relapsed Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
SAKK 06/17
Swiss Cancer Institute
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
PACIFIC BRAZIL
Latin American Cooperative Oncology Group
DUART
AstraZeneca
DUNE
Grupo Espanol de Tumores Neuroendocrinos
IMMUNOPRESERVE
Spanish Oncology Genito-Urinary Group
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
CALYPSO
Queen Mary University of London
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Asan Medical Center
COAST
MedImmune LLC
MIMIPAC
University Hospital, Gasthuisberg
Durvalumab in HIV-1 Patients With Solid Tumors
Spanish Lung Cancer Group
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
AstraZeneca
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
Pulmonary sarcomatoid_MEDI4736+Treme
Seoul National University Hospital
FRAIL-IMMUNE
Centre Leon Berard
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
AstraZeneca
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
SAFIR02_Lung
UNICANCER
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Academic Thoracic Oncology Medical Investigators Consortium
SUKSES-N4
Samsung Medical Center
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Study of Tremelimumab in Patients With Advanced Solid Tumors
AstraZeneca
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Weill Medical College of Cornell University